Tithon Human Sciences, Inc., announced the opening of its second Tithon Regenerative Centre located in Kuala Lumpur, Malaysia, providing Asia, India and the Middle East access to Tithon’s advanced cellular technologies developed to address degenerative medical conditions, including aging and infertility.
Tithon Human Sciences, Inc., announced today that it has opened its second Tithon Regenerative Centre, located in Kuala Lumpur, Malaysia. Tithon’s Chairman and Chief Executive Officer, Dr. Vasilis Paspaliaris noted that, to date, Tithon has established proprietary Tithon Regenerative Centres in Melbourne Australia and Kuala Lumpur, Malaysia and plans to open two additional proprietary Tithon Regenerative Centres, one in Alexandroupolis, Greece and one in San Diego, California, USA by the middle of 2017. Each Tithon Regenerative Centre is dedicated to the development and support of carefully selected and qualified Licensed Clinic Locations, each offering one or more of Tithon’s advanced technologies, products, methods, processes and procedures in their practice of medicine. From Tithon Regenerative Centres, physicians and technicians within Licensed Clinic Locations are provided: (i) initial and ongoing training and education regarding regenerative medicine, utilizing Tithon’s advanced technologies, products, methods, processes and procedures; (ii) logistical support for the Tithon consumables provided to Clinic Location Licensees in their geographical continental areas; and (iii) ongoing support to local ongoing research & development programs.
About Tithon Human Sciences, Inc. Tithon Human Sciences, Inc. is a California corporation (the “Company”) formed, as a wholly owned subsidiary of Tithon Biotech, Inc., a Delaware corporation (“Tithon Biotech”), to undertake the commercialization of certain technologies, including products, methods, processes and procedures, along with related intellectual property, developed by pioneers in the field of cell therapies (collectively the “Tithon Technologies”) to address human degenerative medical conditions, including aging and infertility. The Company has been granted licenses to market and license these Tithon Technologies to clinics and medical practices throughout the world engaged in the treatment of human degenerative medical conditions (“Licensed Clinic Locations”), which it has undertaken through its Tithon Regenerative Centres. Currently, the Company, through its Tithon Regenerative Centres, offers to Licensed Clinic Locations one or more of the following Tithon Technologies: (i) A proprietary method and process for recovering therapeutic quantities of a non-immunogenic parathyroid hormone receptor positive pluripotent stem cells derived from peripheral blood that exhibits potential in both regenerative and therapeutic procedures in humans (the PTHR-PSC Technology); (ii) A proprietary method and process for recovering paternal antigens derived from the male partner’s or donor’s lymphocyte membranes for use in increasing female immune tolerance to paternal antigens (the “LMIT Technology”); (iii) A proprietary method and process for collecting, processing and photo-activating adipose-derived stem cells (the “Adistem Technology”); (iv) A proprietary method and process for performing antigen-specific immunotherapy addressing many autoimmune disorders (the “Desense Technology”); (v) A proprietary method and process for injection of a unique protein that stimulates the expression and activity of cellular telomerase (the “Telomax Technology”); and (vi) A proprietary method and process for promoting new hair growth through the implantation of a small amount of adipose tissue removed from the abdomen, via lipoaspiration, combined with peripheral blood-derived pluripotent stem cells utilizing the PTHR-PSC Technology (the “Trichogenesis Technology”).
These Tithon Technologies are utilised in addressing degenerative medical conditions, including anti-aging and infertility, through carefully selected Licensed Clinic Locations, each of which has proven capable of providing the highest quality care, supported by rigorous controls, dedication to ongoing training, and supported by proprietary information. See www.tithonhuman.com